VEGFA and liver disorder: Similarly, major pathways (111/121) are also modulated with adjusted p-values < 0.05, and many of them have been proved as suitable therapeutic pathways for CVDs and liver diseases, such as cGMP-PKG (cyclic guanosine monophosphate-dependent protein kinase) signaling pathway (hsa04022), VEGF (vascular endothelial growth factor) signaling pathway (hsa04370), Platelet activation (hsa04611), NAFLD (hsa04022), Hepatitis B (hsa05161), Hepatitis C (hsa05160), Hepatocellular carcinoma (hsa05225), and drug metabolism–cytochrome P450 (hsa00982).